GBA-associated PD: Chances and Obstacles for Targeted Treatment Strategies

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2022 May 31

PMID 35639160

Authors

Gunter Hoglinger

Claudia Schulte

Wolfgang H Jost

Alexander Storch

Dirk Woitalla

Rejko Kruger

Bjorn Falkenburger

Kathrin Brockmann

Affiliations

Soon will be listed here.

Abstract

Given the clear role of GBA in the pathogenesis of Parkinson's disease (PD) and its impact on phenotypical characteristics, this review provides an overview of the current knowledge of GBA-associated PD with a special focus on clinical trajectories and the underlying pathological mechanisms. Importantly, differences and characteristics based on mutation severity are recognized, and current as well as potential future treatment options are discussed. These findings will inform future strategies for patient stratification and cohort enrichment as well as suitable outcome measures when designing clinical trials.

Citing Articles

Updated MDSGene review on the clinical and genetic spectrum of LRRK2 variants in Parkinson´s disease.

Kruger C, Lim S, Buhrmann A, Fahrig F, Gabbert C, Bahr N NPJ Parkinsons Dis. 2025; 11(1):30.

PMID: 39962078 PMC: 11832785. DOI: 10.1038/s41531-025-00881-9.

Combining Biomarkers with Genetics In Prodromal/Earliest Phase Parkinson's Disease.

Seibler P, Streubel-Gallasch L, Klein C J Parkinsons Dis. 2024; 14(s2):S345-S351.

PMID: 39331107 PMC: 11492027. DOI: 10.3233/JPD-240155.

Parkinson's Disease Gene Screening in Familial Cases from Central and South America.

Lorenzo-Betancor O, Mehta S, Ramchandra J, Mumuney S, Schumacher-Schuh A, Cornejo-Olivas M Mov Disord. 2024; 39(10):1843-1855.

PMID: 39051491 PMC: 11490405. DOI: 10.1002/mds.29931.

Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2 - Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease.

Dobert J, Bub S, Machtel R, Januliene D, Steger L, Regensburger M Adv Sci (Weinh). 2024; 11(25):e2401641.

PMID: 38666485 PMC: 11220700. DOI: 10.1002/advs.202401641.

Case-Fatality Rate in Parkinson's Disease: A Nationwide Registry Study.

Sipila J, Kaasinen V, Rautava P, Kyto V Mov Disord Clin Pract. 2024; 11(2):152-158.

PMID: 38386489 PMC: 10883402. DOI: 10.1002/mdc3.13948.

References

Chen J, Li W, Zhang T, Wang Y, Jiang X, Xu Z . Glucocerebrosidase gene mutations associated with Parkinson's disease: a meta-analysis in a Chinese population. PLoS One. 2014; 9(12):e115747. PMC: 4275276. DOI: 10.1371/journal.pone.0115747. View

Barrett M, Shanker V, Severt W, Raymond D, Gross S, Schreiber-Agus N . Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease. JIMD Rep. 2014; 16:31-8. PMC: 4221612. DOI: 10.1007/8904_2014_315. View

Migdalska-Richards A, Daly L, Bezard E, Schapira A . Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol. 2016; 80(5):766-775. PMC: 5132106. DOI: 10.1002/ana.24790. View

Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F . Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Neurobiol Dis. 2015; 82:235-242. DOI: 10.1016/j.nbd.2015.06.008. View

Alcalay R, Levy O, Waters C, Fahn S, Ford B, Kuo S . Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain. 2015; 138(Pt 9):2648-58. PMC: 4564023. DOI: 10.1093/brain/awv179. View

Lerche S, Machetanz G, Wurster I, Roeben B, Zimmermann M, Pilotto A . Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile. Mov Disord. 2019; 34(7):1069-1073. DOI: 10.1002/mds.27731. View

Jo J, Yang L, Tran H, Yu W, Sun A, Chang Y . Lewy Body-like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α-Synuclein Mutations. Ann Neurol. 2021; 90(3):490-505. PMC: 9543721. DOI: 10.1002/ana.26166. View

Alcalay R, Wolf P, Chiang M, Helesicova K, Zhang X, Merchant K . Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. Ann Clin Transl Neurol. 2020; 7(10):1816-1830. PMC: 7545591. DOI: 10.1002/acn3.51164. View

Pal G, Mangone G, Hill E, Ouyang B, Liu Y, Lythe V . Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022; 91(3):424-435. PMC: 8857042. DOI: 10.1002/ana.26302. View

10.

Rocha E, Smith G, Park E, Cao H, Brown E, Hayes M . Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015; 82:495-503. DOI: 10.1016/j.nbd.2015.09.009. View

11.

Hein L, Meikle P, Hopwood J, Fuller M . Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab. 2007; 92(4):336-45. DOI: 10.1016/j.ymgme.2007.08.001. View

12.

Zunke F, Moise A, Belur N, Gelyana E, Stojkovska I, Dzaferbegovic H . Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron. 2018; 97(1):92-107.e10. PMC: 6013314. DOI: 10.1016/j.neuron.2017.12.012. View

13.

Aarsland D, Perry R, Brown A, Larsen J, Ballard C . Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol. 2005; 58(5):773-6. DOI: 10.1002/ana.20635. View

14.

Avenali M, Toffoli M, Mullin S, McNeil A, Hughes D, Mehta A . Evolution of prodromal parkinsonian features in a cohort of mutation-positive individuals: a 6-year longitudinal study. J Neurol Neurosurg Psychiatry. 2019; 90(10):1091-1097. DOI: 10.1136/jnnp-2019-320394. View

15.

Paciotti S, Gatticchi L, Beccari T, Parnetti L . Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. Clin Chim Acta. 2019; 495:13-24. DOI: 10.1016/j.cca.2019.03.1627. View

16.

Brockmann K, Lerche S, Dilger S, Stirnkorb J, Apel A, Hauser A . SNPs in Aβ clearance proteins: Lower CSF Aβ levels and earlier onset of dementia in PD. Neurology. 2017; 89(23):2335-2340. DOI: 10.1212/WNL.0000000000004705. View

17.

Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F . Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology. 2012; 78(6):417-20. DOI: 10.1212/WNL.0b013e318245f476. View

18.

Elleder M . Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis. 2006; 29(6):707-15. DOI: 10.1007/s10545-006-0411-z. View

19.

Heckman M, Soto-Ortolaza A, Contreras M, Murray M, Pedraza O, Diehl N . LRRK2 variation and dementia with Lewy bodies. Parkinsonism Relat Disord. 2016; 31:98-103. PMC: 5048558. DOI: 10.1016/j.parkreldis.2016.07.015. View

20.

Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C . Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet. 2010; 20(1):202-10. DOI: 10.1093/hmg/ddq454. View